





## securAcath® provides secure fixation throughout the life of the catheter

Insufficient fixation of venous catheters leads to a higher risk of migration and accidental removal, which can lead to :

- Bacterial migration
- Catheter-related bloodstream infection
- Venous thrombosis
- Treatment delays
- Catheter replacement<sup>1</sup>



### Benefits of securAcath®





- Clinical studies conducted with SecurAcath® show a dislodgement rate of 0 1.5%¹-6 versus 14 20% for adhesive fixation devices⁻-8.
- Reduced catheter replacement costs: the cost of replacing the PICC is approximately \$1,000 in Interventional Radiology<sup>9</sup>.

### Less migration



- The migration of the catheter at the insertion site can introduce bacteria under the skin. 10
- Enhanced stability can promote healing at the insertion site, which acts as a natural barrier against infection.
- · May reduce phlebitis, thrombosis and infection

## More efficiency

- securAcath® provides safety for the entire life of the catheter.
- The catheter remains secure during dressing changes.
- Allows easy repositioning of the catheter if the distal end of the catheter must be removed.



## • Safe 360-degree disinfection of the insertion site

- Excellent access all around the insertion site.
- The catheter remains stable and secure during disinfection.

## securAcath® eliminates the risk of medical adhesive-related skin injury\*



## No risk of needlestick injury

- Eliminates the risk of needlestick injuries related to the use of sutures.
- The average cost of needlestick injuries is \$825<sup>11-14</sup>.
- There are more than 92,000 needlestick injuries to healthcare workers in the United States each year<sup>15</sup>.

<sup>\*</sup> Infusion Therapy Standards of Practice, Journal of Infusion Nursing, Vol. 39, No. 1S, Jan/Feb 2016





# securAcath® is the only subcutaneous anchor securement system

### • Complies with Infusion Therapy Standards of Practice 2016\*:

- « Subcutaneous anchor securement systems have been successful in stabilizing PICCs and CVADs »
- « Patient outcomes and patient and inserter satisfaction have been favorable »

### • Recommended by the National Institute for Health and Care Excellence\*\*:

- « SecurAcath® is easy to insert, well tolerated, associated with a low incidence of catheter-related complications and does not usually need removing while the catheter is in place. »
- « securA**cath**® should be considered for any PICC with an anticipated medium- to long-term dwell time (15 days or more).»
- « Cost modelling shows that securAcath® is cost saving compared with adhesive securement devices if the PICC remains in place for 15 days or longer. Cost savings result from shorter maintenance times and less need for device replacement with SecurAcath. Annual savings across the NHS in England from using securAcath® are estimated to be a minimum of £4.2 million. »







Clip



## Commercial references

Code	Size	Qty/box
400130	3 F	10
400140	4 F	10
400110	5 F	10
400150	6 F	10
400120	7 F	10
400160	8 F	10
400180	10 F	10
400200	12 F	10

### Further information on securAcath®:

- Not made with natural latex
- MRI compatible under conditions (see instructions for use)

<sup>\*\*</sup> https://www.nice.org.uk/guidance/mtg34/chapter/1-Recommendations





- 1. Hughes, M., Reducing PICC Migrations and Improving Patient Outcomes, British Journal of Nursing, January 2014; Vol. 23, No. 2, pg. 16-21.
- 2. Egan, G., Siskin, G., Weinmann, R., Galloway, M., A Prospective Postmarket Study to Evaluate the Safety and Efficacy of a New Peripherally Inserted Central Catheter Stabilization System.

  J Infus Nurs. 2013; 36(3): 181-188.
- 3. Sandeluss, S., Price, N., Simcock, L. and Patel, B., Central Venous Access, Cancer Services University College London Hospital NHS Foundation Trust. Introducing SecurAcath into a Haematology/ Oncology Setting. Poster Presentation AVA 2013
- 4. Stone, L. MSN, RN, VA-BC, Lamagna, P. BSN, RN, VA-BC, Pratt, P. MA, RN, CPN, NE-BC, Boston Children's Hospital, Boston, MA. Improving PICC Care in the Pediatric Patient. Poster Presentation AVA 2013
- Dougherty, L. RN, DClinP, MSc, Nurse Consultant, Intravenous Therapy, Nursing, Rehabilitation & Quality Assurance, The Royal Marsden NHS Foundation Trust. Securing a More Stable PICC. Poster Presentation AVA 2013
- 6. Balance, P. BS, RN-BC, VA-BC, Grant, A. RN, VA-BC, Wayne Memorial Hospital, Goldsboro, NC. Cutting Edge Technology: Central Venous Line Securement Device.

Poster Presentation AVA 2013

- 7. Broadhurst, D., Mallick, R., Ottawa Hospital Research Institute, Ottawa, ON, Canada. PICC Securement Dressings A Randomized Controlled Trial in the Homecare Setting. Association for Vascular Access 2014, Poster C3
- 8. Hill, J. MN, RN, OCN, CVAA(c), VA-BC, St Paul's Hospital, Vancouver, BC, Canada. Beyond the Dressing for PICCs Strategy for Cost-Savings and Work Efficiency. Oral Presentation, World Congress Vascular Access, June 2014
- 9. Cardella et al., Cumulative experience with 1,273 peripherally inserted central catheters at a single institution. JVIR 1996; 7:5-13.
- 10. Abebe, A., Catheter-Related Bloodstream Infection Review. Hosp Med Clin, Jan. 2014, (3) e32-e49.
- 11. Jagger, J., Direct Cost of Follow-up for Percutaneous and Mucocutaneous Exposures to At-Risk Body Fluids: Data from Two Hospitals. Adv Expos Prev, 1998. 3(3):25-34.
- 12. Lee, W.C., Short-term Economic Impact Associated with Occupational Needlestick Injuries Among Acute Care Nurses. Current Medical Research and Opinion, 2005. 21(12): 1915-1922.
- 13. O'Malley, E.M., Cost of Management of Occupational Exposures to Blood and Body Fluids. Infect Control Hosp Epidemiol. 2007. 28(7):774-782.
- 14. CDC, Workbook for Designing, Implementing and Evaluating a Sharps Injury Prevention Program. 2008: 1-168.
- 15. Centers for Disease Control and Prevention, Stop Sticks Campaign. www.cdc.gov/niosh/stopsticks.

Interrad Medical and securAcath® are registered trademarks of Interrad Medical, Inc.

Manufacturer:



1-866-980-1811 www.securacath.com **Authorized Representative:** 

MDSS GmbH Schiffgraben 41 30175 Hanovre, Allemagne +49 511 6262 8630

## INTRAVASCULAR THERAPIES

#### For further information, please contact: marketingbenelux@vygon.com

The specifications shown in this leaflet are for information only and are not, under any circumstances, of a contractual nature.

